<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087165</url>
  </required_header>
  <id_info>
    <org_study_id>PMH-PHL-024</org_study_id>
    <secondary_id>CDR0000372951</secondary_id>
    <secondary_id>NCI-6102</secondary_id>
    <nct_id>NCT00087165</nct_id>
  </id_info>
  <brief_title>GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Phase II Study of GTI-2040 in Combination With Docetaxel and Prednisone in Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      RATIONALE: GTI-2040 may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. GTI-2040 may help docetaxel kill more&#xD;
      tumor cells by making them more sensitive to the drug.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving GTI-2040 together with docetaxel and&#xD;
      prednisone works in treating patients with prostate cancer that has not responded to hormone&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of GTI-2040, docetaxel, and prednisone, in terms of&#xD;
           prostate-specific antigen (PSA) response rate, in patients with hormone-refractory&#xD;
           prostate cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine objective tumor response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the median time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the median duration of PSA response in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate baseline and post-treatment levels of ribonucleotide reductase activity in&#xD;
           tumor biopsies and peripheral blood mononuclear cells and tumoral expression of c-myc,&#xD;
           R2 subunit protein, and markers of cellular proliferation and apoptosis with clinical&#xD;
           outcomes in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive GTI-2040 IV continuously on days 1-14, docetaxel IV on day 3 of course 1 and&#xD;
      on day 1 of subsequent courses, and oral prednisone twice daily on days 1-21. Treatment&#xD;
      repeats every 21 days for up to 10 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-46 patients will be accrued for this study within 3.6-9.5&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate and duration</measure>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GTI-2040</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic carcinoma of presumptive prostate origin&#xD;
&#xD;
                    -  Bony metastases AND a serum prostate-specific antigen (PSA) level &gt; 20 ng/mL&#xD;
&#xD;
          -  Disease progression after prior hormonal therapy as defined by rising PSA levels&#xD;
&#xD;
               -  At least 2 consecutive rises in PSA over a reference value, with measurements&#xD;
                  taken at least 7 days apart&#xD;
&#xD;
               -  Prior hormonal therapy must include either medical (luteinizing hormone-releasing&#xD;
                  hormone [LHRH] agonist) OR surgical (orchiectomy) castration&#xD;
&#xD;
                    -  Patients who received prior LHRH agonist must continue or re-start such&#xD;
                       therapy&#xD;
&#xD;
          -  Castrate levels of testosterone &lt; 50 ng/dL&#xD;
&#xD;
          -  PSA ≥ 20 ng/mL&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  PTT ≤ 1.25 times upper limit of control&#xD;
&#xD;
          -  INR ≤ 1.3&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to GTI-2040 or other study agents&#xD;
&#xD;
          -  No concurrent uncontrolled illness&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) or epoetin alfa&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy except monotherapy with oral estramustine&#xD;
&#xD;
          -  At least 4 weeks since prior estramustine and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior bicalutamide*&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide, nilutamide, or cyproterone*&#xD;
&#xD;
          -  Concurrent steroids allowed NOTE: *Patients must have evidence of disease progression&#xD;
             despite cessation of antiandrogen therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  No prior isotope therapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent prophylactic antibiotics&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
               -  Concurrent low-dose warfarin for prophylaxis of central line thrombosis allowed&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm J. Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2011 Apr;67(4):927-33. doi: 10.1007/s00280-010-1389-7. Epub 2010 Jul 3.</citation>
    <PMID>20602233</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

